1. Immunology/Inflammation
  2. NOD-like Receptor (NLR)
  3. MCC950 sodium

MCC950 sodium  (Synonyms: CP-456773 sodium; CRID3 sodium salt)

目录号: HY-12815A 纯度: 99.75%
COA 产品使用指南

MCC950 sodium (CP-456773 sodium; CRID3 sodium salt) 是一种有效,选择性的 NLRP3 抑制剂,在BMDMs 和 HMDMs中的 IC50 分别为 7.5 nM 和 8.1 nM。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

MCC950 sodium Chemical Structure

MCC950 sodium Chemical Structure

CAS No. : 256373-96-3

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥660
In-stock
5 mg ¥600
In-stock
10 mg ¥910
In-stock
25 mg ¥1900
In-stock
50 mg ¥3200
In-stock
100 mg ¥3975
In-stock
200 mg ¥5813
In-stock
500 mg 现货 询价
1 g   询价  
5 g   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of MCC950 sodium:

MCE 顾客使用本产品发表的 291 篇科研文献

WB
IF

    MCC950 sodium purchased from MCE. Usage Cited in: J Agric Food Chem. 2023 May 4.  [Abstract]

    MCC950 (10 μM; 2 h) markedly inhibits the expressionof NLRP3, Cleaved Caspase-1, and Cleaved IL-1β in HUVECs.

    MCC950 sodium purchased from MCE. Usage Cited in: Int J Mol Sci. 2023 Mar 27.

    MCC950 (5 μM; every other day for four weeks) significantly decreases CD68+ and GSDMD+ cells in rats.

    MCC950 sodium purchased from MCE. Usage Cited in: Journal of Traditional and Complementary Medicine. 2023 Mar 29.

    MCC950 (10 μM; 1 h) inhibits the expression of NLRP3 in THP-1 cells.

    MCC950 sodium purchased from MCE. Usage Cited in: EMBO J. 2022 Oct 17;e111173.  [Abstract]

    BMDMs isolated from Phb1F/F mice and Phb1MyeKO mice are incubated with MCC950 (50 nM) for 30 min and are subsequently stimulated by LPS (200 ng/ml) for 6 h and ATP (4 mM) for 45 min. Protein levels in whole cell lysates and culture medium are detected by WB assay.

    MCC950 sodium purchased from MCE. Usage Cited in: J Neuroinflammation. 2018 Mar 24;15(1):95.  [Abstract]

    Chronic PVN infusion of MCC950 significantly decreases apoptosis-associated speck-like protein (ASC), pro-caspase-1, and IL-1β expression in high-salt diet rats.

    MCC950 sodium purchased from MCE. Usage Cited in: Cell Death Dis. 2018 Sep 20;9(10):946.   [Abstract]

    The efficiency of MCC950, and its effect on caspase-1 activation and IL-1β production in As2O3-treated HepG2 cells.

    MCC950 sodium purchased from MCE. Usage Cited in: Neurobiol Dis. 2018 Sep;117:15-27.  [Abstract]

    Effect of MCC950 on the expression of NLRP3 inflammasome components and substrates after traumatic brain injury (TBI).

    MCC950 sodium purchased from MCE. Usage Cited in: Biofactors. 2018 Mar;44(2):123-136.  [Abstract]

    NLRP3, Casp1 p20, IL-1b, and ICAM-1 protein levels are assessed in the cell lysates by Western blotting.

    MCC950 sodium purchased from MCE. Usage Cited in: Clin Exp Immunol. 2018 Nov;194(2):231-243.  [Abstract]

    MCC950 treatment inhibits Nucleotide-binding, oligomerization domain (NOD)-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome pathway activation.

    MCC950 sodium purchased from MCE. Usage Cited in: Molecules. 2018 Feb 27;23(3). pii: E522.  [Abstract]

    Effects of MCC950 on hippocampal NLRP3 inflammasome activation in db/db mice. Western blot analysis of NLRP3 inflammasome-associated NLRP3, ASC, IL-1β, and β-actin are performed in the hippocampus of each group.

    MCC950 sodium purchased from MCE. Usage Cited in: Dig Dis Sci. 2018 Jan;63(1):81-91.  [Abstract]

    The expression of various molecules in pyroptotic and apoptotic pathways is detected by western blot. Representative bands from densitometric analysis in experimental groups are presented. M, MCC950 group (an inhibitor of NLRP3).

    MCC950 sodium purchased from MCE. Usage Cited in: J Am Heart Assoc. 2017 Sep 4;6(9). pii: e006347.  [Abstract]

    Cells are pretreated with YVAD(10 μM) or MCC950 (10 μM) for 2 hours, and then exposed to TMAO (600 μM) for a further 24 hours. Expression of IL-1β, ICAM-1, MMP-9, and caspase-1 p20 is detected via Western blot.

    MCC950 sodium purchased from MCE. Usage Cited in: Biochim Biophys Acta. 2017 Oct 3;1864(1):1-10.  [Abstract]

    MCC950 or vehicle control (PBS) is administered at 1, 4 and 6 day after Ang II infusion in the absence or presence of EMD638683. Representative images and quantification of picrosirius red-stained collagen in the heart at 7 days after Ang II infusion.

    查看 NOD-like Receptor (NLR) 亚型特异性产品:

    • 生物活性

    • 实验参考方法

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    MCC950 sodium (CP-456773 sodium; CRID3 sodium salt) is a potent, selective NLRP3 inhibitor with IC50s of 7.5 and 8.1 nM in BMDMs and HMDMs, respectively.

    IC50 & Target

    NLRP3

     

    体外研究
    (In Vitro)

    MCC950 在纳摩尔浓度下阻断经典和非经典 NLRP3 激活。MCC950 特异性抑制 NLRP3,但不抑制 AIM2、NLRC4 或 NLRP1 激活。MCC950 对 NLRP3 炎性体激活的影响在小鼠骨髓来源的巨噬细胞 (BMDM) 和人单核细胞来源的巨噬细胞 (HMDM) 中进行了测试。MCC950 在 BMDM 中的 IC50 约为 7.5 nM,而在 HMDM 中具有相似的抑制能力 (IC50=8.1 nM)。MCC950 还剂量依赖性地抑制 IL-1β 但不抑制 TNF-α 分泌。MCC950 在非经典途径刺激时特异性阻断 caspase-11 定向的 NLRP3 激活和 IL-1β 分泌。NLRC4 刺激的 IL-1β 和 TNF-α 分泌 (被鼠伤寒沙门氏菌激活) 即使在 10 μM 的浓度下也不会被 MCC950 抑制。MCC950 不抑制响应鼠伤寒沙门氏菌的 caspase-1 激活或 IL-1β 加工。pro-caspase-1 和 pro-IL-1β 在细胞裂解物中的表达基本上不受 MCC950 处理的影响[1]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    体内研究
    (In Vivo)

    MCC950 减少白细胞介素-1p (IL-1β) 的产生并减轻实验性自身免疫性脑脊髓炎 (EAE) 的严重程度,EAE 是一种多发性硬化症的疾病模型。用 MCC950 预处理可降低 IL-1β 和 IL-6 的血清浓度,同时不会显著降低 TNF-α 的量。用 MCC950 处理小鼠可延迟 EAE 的发作并降低其严重程度。第 22 天处死的小鼠脑单核细胞的细胞内细胞因子染色和 FACS 分析显示,与 PBS 处理的小鼠相比,MCC950 处理的小鼠中产生 IL-17IFN-γCD3+ T 细胞的频率适度降低。CD3+ T 的 CD4+ 和 γδ+ 亚群中产生 IFN-γ 尤其是 IL-17 的细胞数量也减少[1]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    分子量

    426.46

    Formula

    C20H23N2NaO5S

    CAS 号
    性状

    固体

    颜色

    Off-white to yellow

    运输条件

    Room temperature in continental US; may vary elsewhere.

    储存方式

    4°C, sealed storage, away from moisture

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    溶解性数据
    细胞实验: 

    DMSO 中的溶解度 : 100 mg/mL (234.49 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

    H2O 中的溶解度 : ≥ 30 mg/mL (70.35 mM)

    * "≥" means soluble, but saturation unknown.

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 2.3449 mL 11.7244 mL 23.4489 mL
    5 mM 0.4690 mL 2.3449 mL 4.6898 mL
    查看完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

    * 备注:如您选择水作为储备液,请稀释至工作液后,再用 0.22 μm 的滤膜过滤除菌后使用。

    • 摩尔计算器

    • 稀释计算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量
    =
    浓度
    ×
    体积
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start)

    C1

    ×
    体积 (start)

    V1

    =
    浓度 (final)

    C2

    ×
    体积 (final)

    V2

    动物实验:

    请根据您的 实验动物和给药方式 选择适当的溶解方案。

    以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
    ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
    以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

    • 方案 一

      请依序添加每种溶剂: 5% DMSO    95% PBS

      Solubility: ≥ 5 mg/mL (11.72 mM); 澄清溶液

    • 方案 二

      请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (5.86 mM); 澄清溶液

      此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液。

      1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中,混合均匀。

      2 g SBE-β-CD(磺丁基醚 β-环糊精)粉末定容于 10 mL 的生理盐水中,完全溶解至澄清透明。

    以下溶解方案,请直接配制工作液。建议现用现配,在短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶。

    • 方案 一

      请依序添加每种溶剂: PBS

      Solubility: 6.25 mg/mL (14.66 mM); 澄清溶液; 超声助溶

    动物溶解方案计算器
    请输入动物实验的基本信息:

    给药剂量

    mg/kg

    动物的平均体重

    g

    每只动物的给药体积

    μL

    动物数量

    由于实验过程有损耗,建议您多配一只动物的量
    计算结果
    工作液所需浓度 : mg/mL
    该产品水溶性佳,请具体参考实测 水 / PBS / Saline 中的溶解度数据。
    您所需的储备液浓度超过该产品的实测溶解度,如有需要,请与 MCE 中国技术支持联系。
    纯度 & 产品资料

    纯度: 99.75%

    参考文献
    Cell Assay
    [1]

    BMDM are seeded at 5×105/mL or 1×106/mL, HMDM at 5×105/mL and PBMC at 2×106/mL or 5×106/mL in 96 well plates. The following day the overnight medium is replaced and cells are stimulated with 10 ng/mL LPS from Escherichia coli serotype EH100 (ra) TLRgrad for 3 h. Medium is removed and replaced with serum free medium (SFM) containing DMSO (1:1,000), MCC950 (0.001-10 µM), Parthenolide (10 µM) or Bayer cysteinyl leukotriene receptor antagonist 1-(5-carboxy-2{3-[4-(3-cyclohexylpropoxy)phenyl]propoxy}benzoyl)piperidine-4-carboxylic acid (40 µM) for 30 min. Cells are then stimulated with inflammasome activators: 5 mM adenosine 5’-triphosphate disodium salt hydrate (ATP) (1 h), 1 µg/mL Poly(deoxyadenylic-thymidylic) acid sodium salt (Poly dA:dT) transfected with Lipofectamine 200 (3-4 h), 200 µg/mL MSU (overnight) and 10 µM nigericin (1 h) or S. typhimurium UK-1 strain. Cells are also stimulated with 25 µg/mL Polyadenylic-polyuridylic acid (4 h). For non-canonical inflammasome activation cells are primed with 100 ng/mL Pam3CSK4 for 4 h, medium is removed and replaced with SFM containing DMSO or MCC950 and 2 µg/mL LPS is transfected using 0.25% FuGENE for 16 h. Supernatants are removed and analysed using ELISA kits. LDH release is measured using the CytoTox96 non-radioactive cytotoxicity assay[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [1]

    Mice[1]
    C57BL/6 mice are immunized subcutaneously with 150 µg of MOG peptide 35-55 emulsified in CFA containing 4 mg/mL (0.4.mg/mouse) of heat-killed MTB. Mice are injected i.p. with 500 ng pertussis toxin (PT: kaketsuken) on days 0 and 2. MCC950 is administered i.p. to mice (10 mg/kg) at induction of the disease, day 0, 1 and 2 and every 2 days thereafter. Control mice are administered vehicle (PBS) at the same time points. Mice are observed for clinical signs of disease daily (unblinded). Disease severity is scored as follows: no clinical signs, 0; limp tail, 1; ataxic gait, 2; hind limb weakness, 3; hind limb paralysis, 4; and tetra paralysis, 5.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    参考文献

    完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

    可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO 1 mM 2.3449 mL 11.7244 mL 23.4489 mL 58.6221 mL
    5 mM 0.4690 mL 2.3449 mL 4.6898 mL 11.7244 mL
    10 mM 0.2345 mL 1.1724 mL 2.3449 mL 5.8622 mL
    15 mM 0.1563 mL 0.7816 mL 1.5633 mL 3.9081 mL
    20 mM 0.1172 mL 0.5862 mL 1.1724 mL 2.9311 mL
    25 mM 0.0938 mL 0.4690 mL 0.9380 mL 2.3449 mL
    30 mM 0.0782 mL 0.3908 mL 0.7816 mL 1.9541 mL
    40 mM 0.0586 mL 0.2931 mL 0.5862 mL 1.4656 mL
    50 mM 0.0469 mL 0.2345 mL 0.4690 mL 1.1724 mL
    60 mM 0.0391 mL 0.1954 mL 0.3908 mL 0.9770 mL
    DMSO 80 mM 0.0293 mL 0.1466 mL 0.2931 mL 0.7328 mL
    100 mM 0.0234 mL 0.1172 mL 0.2345 mL 0.5862 mL

    * 备注:如您选择水作为储备液,请稀释至工作液后,再用 0.22 μm 的滤膜过滤除菌后使用。

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称:

     

    * 需求量:

    * 客户姓名:

     

    * Email:

    * 电话:

     

    * 公司或机构名称:

       留言给我们:

    Bulk Inquiry

    Inquiry Information

    产品名称:
    MCC950 sodium
    目录号:
    HY-12815A
    需求量: